1/7/2020 7:02:02 AM
Synthetic Biologics Gets FDA Guidance At Type C Meeting For SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial
9/26/2019 7:15:40 AM
Synthetic Biologics Strengthens U.S. Patent Coverage Of SYN-010
7/1/2019 7:11:43 AM
Synthetic Biologics Regains Compliance With NYSE American Continued Listing Standards
5/8/2019 4:13:47 PM
Synthetic Biologics Q1 Loss/share $0.25 Vs. Loss $0.65 Year Ago
1/3/2019 7:09:01 AM
Synthetic Biologics Announces First Two Patients Enrolled In Phase 2b Investigator-Sponsored Clinical Study Of SYN-010
12/4/2018 1:08:52 PM
Orchestra BioMed Appoints Evan Ballantyne As CFO
11/21/2018 7:03:00 AM
Synthetic Biologics Announces Positive Outcome Of End-of-Phase 2 Meeting With FDA On SYN-004 Development
10/15/2018 2:01:17 PM
Synthetic Biologics Closes $18.64 Mln Public Offering
10/11/2018 9:08:55 AM
Synthetic Biologics Prices $18 Mln Public Offering
9/6/2018 7:20:17 AM
Synthetic Biologics Enters Agreement With Cedars-Sinai Medical Center For Phase 2 Clinical Study Of SYN-010
8/1/2018 5:09:46 PM
Synthetic Biologics Announces Reverse Stock Split Of Common Stock At Ratio Of 1:35 Shares
5/22/2018 7:03:48 AM
Synthetic Biologics Announces Acceptance Of Compliance Plan By NYSE American
2/26/2016 8:43:47 AM
FBR Capital Markets Initiates Synthetic Biologics Inc. (SYN) At Outperform With $10 Price Target
10/13/2015 7:50:50 AM
RBC Capital Markets Starts Synthetic Biologics Inc. (SYN) At Outperform With $2.27 Price Target